-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
"Pharmaceutical Network Industry Dynamics" September 3, Fujian Provincial Drug Administration issued the 2020 No. 2 drug quality notice shows that 26 batches of drugs were found to be unqualified, involving grain grass, straw, smallpox, jaundice, robe leaves, gold and silver flowers, moths, car grass and a large number of Chinese herbs.
, 13 of the 26 batches of non-conforming drugs were rice buds.
The Fujian Provincial Drug Administration said that drug regulatory departments at all levels have organized investigations and prosecutions in accordance with the law for drugs and related units that do not comply with the above-mentioned test results.
Is unique, on the 20th of last month, the State Drug Administration issued the "Notice on 25 batches of drugs do not meet the requirements" (No. 55 of 2020), a total of 25 batches of drugs were found to be unqualified, including 7 batches, accounting for nearly 30% of Chinese medicine tablets.
in these 7 batches of non-conforming Chinese medicine drink tablets, non-compliant items related to characteristics, identification, content determination, total ash and so on.
For the above-mentioned non-compliant Chinese medicine tablets, the drug supervision and administration department has asked the relevant enterprises and units to take risk control measures such as suspension of sales and use, recall, etc., to investigate the reasons for non-compliance and to carry out effective rectification.
can be seen from the above, Chinese herbal medicine, Chinese medicine tablets are still the focus areas in the drug sampling link.
fact, the quality and safety of Chinese herbal medicine and Chinese medicine tablets have been highly valued by the drug regulatory authorities, and in recent years, the supervision and inspection of relevant departments have been increasing.
drug administration law, which will be in force until the end of 2019, increases the amount of penalties and strengthens the penalties for enterprises that break the law.
Whoever specifies the production or sale of inferior drugs shall confiscate the drugs and illegal proceeds illegally produced or sold, and shall be fined not less than ten times or twenty times the value of the drugs illegally produced or sold; If the value of the illegally retailed drug is less than 10,000 yuan, it shall be calculated at 10,000 yuan; if the circumstances are serious, the company shall be ordered to stop production and rectify the drug approval documents, the drug production license, the drug business license or the medical institution's preparation license.
fact, under the state's increasing sampling and punishment efforts, according to the results of the national drug sampling published in 2019, the pass rate of Chinese medicine tablets test passed 91%, an increase of 3 percentage points over 2018.
also means that China's Chinese herbal medicine and drink tablets product pass rate is increasing year by year, the industry is gradually moving towards standardization direction, drink tablet quality has improved.
but industry experts also said that The long industrial chain of Chinese herbal medicine and drinking tablets, involving more problems, but also more complex, do not hope to solve the problem overnight.
, under the strict supervision of the development of the Chinese medicine industry, the reshuffle of the Chinese medicine market is inevitable.
the future industry will be towards large-scale, standardized production direction.
background, enterprises need to pay more attention to product quality, standardization, standardized production and management, in order to go further.